IP Library Granted Patent US 8,921,514
Granted Patent B2
US 8,921,514 · App. 12/964,027 · Granted Dec 30, 2014

Anti-viral compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,514
App. No.
12/964,027
Granted
Dec 30, 2014
Kind
B2
Abstract

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Claims (22)

1. A compound having Formula I, or a pharmaceutically acceptable salt thereof,

wherein:

X is C 3 -C 12 carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more R A ;

L 1 , L 2 , and L 3 are bond;

A is 5- to 6-membered heterocycle;

B is C 3 -C 12 carbocycle or 3- to 12-membered heterocycle;

D is phenyl, and is optionally substituted with one or more R A ;

Y is —C(R 1 R 2 )N(R 5 )—C(O)-L Y -N(R B ″)C(O)-L S -R E , wherein L Y is C 1 -C 6 alkylene, and R B ″ is hydrogen;

R 1 is hydrogen, and R 2 and R 5 , taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle;

Z is —C(R 8 R 9 )N(R 12 )—C(O)-L Y -N(R B ″)C(O)-L S -R E , wherein L Y and R B ″ are as defined above;

R 8 is hydrogen, and R 9 and R 12 , taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle;

R A is independently selected at each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L S -R E , wherein two adjacent R A , taken together with the atoms to which they are attached and any atoms between the atoms to which they are attached, can optionally form carbocycle or heterocycle;

R E is independently selected at each occurrence from —O—R S , —S—R S , —C(O)R S , —OC(O)R S , —C(O)OR S , —N(R S R S ′), —S(O)R S , —SO 2 R S , —C(O)N(R S R S ′), —N(R S )C(O)R S ′, —N(R S )C(O)N(R S ′R S ″), —N(R S )SO 2 R S ′, —SO 2 N(R S R S ′), —N(R S )SO 2 N(R S ′R S ″), —N(R S )S(O)N(R S ′R S ″), —OS(O)—R S , —OS(O) 2 —R S , —S(O) 2 OR S , —S(O)OR S , —OC(O)OR S , —N(R S )C(O)OR S ′, —OC(O)N(R S R S ′), —N(R S )S(O)—R S ′, —S(O)N(R S R S ′) or —C(O)N(R S )C(O)—R S ′; or C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or C 3 -C 6 carbocycle or 3- to 6-membered heterocycle, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 2 -C 6 haloalkenyl or C 2 -C 6 haloalkynyl;

L S is each independently selected at each occurrence from bond; or C 1 -C 6 alkylene, C 2 -C 6 alkenylene or C 2 -C 6 alkynylene; and

R S , R S ′ and R S ″ are each independently selected at each occurrence from hydrogen; C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; wherein each 3- to 6-membered carbocycle or heterocycle in R S , R S ′ or R S ′ is independently optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C 1 -C 6 alkyl, C 2 ′ C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 2 -C 6 haloalkenyl or C 2 -C 6 haloalkynyl.

2. The compound or salt according to claim 1 , wherein R 2 and R 5 , taken together with the atoms to which they are attached, form

and R 9 and R 12 , taken together with the atoms to which they are attached, form

3. The compound or salt according to claim 2 , wherein B is 5- to 6-membered heterocycle.

4. The compound or salt according to claim 3 , wherein X is a ring system comprising a 6- to 12-membered bicycle which is substituted with one or more R A , and wherein two adjacent R A , taken together with the atoms to which they are attached, form carbocycle or heterocycle.

5. The compound or salt according to claim 3 , wherein D is phenyl.

6. The compound or salt according to claim 4 , wherein D is phenyl.

7. A pharmaceutical composition comprising the compound or salt of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030137/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2011
From: GAO, YI
To: ABBOTT LABORATORIES
Reel/Frame 026775/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2011
From: DEGOEY, DAVID A.; KATI, WARREN M.; HUTCHINS, CHARLES W.; DONNER, PAMELA L.; KRUEGER, ALLAN C.; RANDOLPH, JOHN T.; MOTTER, CHRISTOPHER E.; NELSON, LISSA T.; PATEL, SACHIN V.; MATULENKO, MARK A.; KEDDY, RYAN G.; JINKERSON, TAMMIE K.; SOLTWEDEL, TODD N.; HUTCHINSON, DOUGLAS K.; FLENTGE, CHARLES A.; WAGNER, ROLF; MARING, CLARENCE J.; TUFANO, MICHAEL D.; BETEBENNER, DAVID A.; ROCKWAY, TODD W.; LIU, DACHUN; PRATT, JOHN K.; LAVIN, MICHAEL J.; SARRIS, KATHY; WOLLER, KEVIN R.; WAGAW, SEBLE H.; CALIFANO, JEAN C.; LI, WENKE; CASPI, DANIEL D.; BELLIZZI, MARY E.; CARROLL, WILLIAM A.
To: ABBOTT LABORATORIES
Reel/Frame 026231/0660 →